Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema.

Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema.

Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema.

Campochiaro P.A., Brown D.M., Pearson A., Ciulla T., Boyer D., Holz F.G., Tolentino M., Gupta A., Duarte L., Madreperla S., Gonder J., Kapik B., Billman K., Kane F.E. and FAME Study Group

Ophthalmology 2011; 118(4):626-635

2011

Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.

Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.

Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.

Carneiro A.M., Silva R., Veludo M.J., Barbosa A., Ruiz-Moreno J.M., Falcão M.S., Brandão E.M., Falcão-Reis F.M.

Ophthalmologica 2011;225(2):81-8

2011

Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up.

Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up.

Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up.

Coutinho A.M., Silva R.M., Nunes S.G., Cachulo M.L., Figueira J.P., Murta J.N.

Retina 2011;31(6):1089-94

2011